X
Xian-Yun Chang
Publications - 3
Citations - 54
Xian-Yun Chang is an academic researcher. The author has contributed to research in topics: Regimen & Placebo. The author has an hindex of 2, co-authored 3 publications receiving 11 citations.
Papers
More filters
Journal ArticleDOI
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
Hongxing Pan,Jian-Kai Liu,Baoying Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wenling Wang,Kai Chu,Jialei Hu,Jingxin Li,Dan-Dan Zhu,Jing-Liang Wu,Xiao-Yu Xu,Li Zhang,Meng Wang,Wenjie Tan,Wei-Jin Huang,Fengcai Zhu,Fengcai Zhu +18 more
TL;DR: In this article, the authors report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults, in a phase 1 and phase 2 randomized, double-blind, and placebo-controlled trial.
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
Hong-Xing Pan,Jian-Kai Liu,Baoying Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wen-Ling Wang,Kai Chu,Jialei Hu,Jingxin Li,Dan-Dan Zhu,Jing-Liang Wu,Xiao-Yu Xu,Li Zhang,Meng Wang,Wenjie Tan,Weijin Huang,Fengcai Zhu +17 more
TL;DR: In this article, the authors reported the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults in two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials.
Journal Article
Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials
Hongxing Pan,J. K. Liu,B. Y. Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wei Wang,Kai Chu,Jialei Hu,Jie Li,Dan-Dan Zhu,Jing-Liang Wu,Xiping Xu,Ling Zhang,Mengzhao Wang,Wenjie Tan,W. J. Huang,F. C. Zhu +17 more
TL;DR: In this paper, the authors report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults, in a phase 1 and phase 2 trial.